Off-Label Gabapentin Use Up Despite 'Dearth of Evidence' : v

The drug may be prescribed with sedating medications even after a 2019 warning from the FDA about such combinations.

Related Keywords

Michigan , United States , Ann Arbor , Michaele Johansen , Donovant Maust , , Expenditure Panel , Drug Administration , Ann Arbor Va Center , National Institute On Drug Abuse , Clinical Management Research , University Of Michigan , Expenditure Panel Survey , Grant Family Medicine , Medical Expenditure Panel Survey , National Institute , Pain Management , Back Pain , Spain , Fibromyalgia , Chronic Pain , Neuropathic Pain , Central Nervous System , Ns , Addiction , Multiple Sclerosis Ms , S Multiple Sclerosis , Diabetic Peripheral Neuropathy , Opioids , Drug Abuse , Neuromuscular Blocking Drug , Muscle Relaxant , Neuromuscular Blocking Agent , Peripheral Neuropathy , Postherpetic Neuralgia , Diabetic Neuropathy , Diabetic Neuropathies ,